The emergence of precision medicine is driving a shift in how early-phase oncology trials are conducted. A growing number of Phase 1 trials are reporting preliminary response rates, a trend that reflects an increase in the use of adaptive trial designs that limit the number of patients exposed to ineffective treatments and accelerate the timeline to detection of efficacy signals.

Download Premier Research’s new white paper Adaptive Trial Designs in Early Oncology: Minimizing Risk & Accelerating Timelines for a closer look at how these designs can help you improve the efficiency and flexibility of your study. Topics include:

• The current state of precision medicine in oncology drug research
• Operational elements to consider, starting with whether to include a control group
• Common adaptive design strategies in precision oncology drug development